BIIB

China approves Alzheimer's treatment Leqembi by Eisai and Biogen

Credit: REUTERS/Brian Snyder

TOKYO, Jan 9 (Reuters) - Eisai 4523.T and Biogen BIIB.O said on Tuesday that their Alzheimer's treatment Leqembi had won approval in China, the third country after the United States and Japan.

The two companies are preparing to launch the drug in the second quarter of Eisai's 2024/25 business year starting in April.

Leqembi is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of Alzheimer's patients. It is the first treatment shown to slow progression of the disease for people in the earlier stages of Alzheimer's.

Japan approved the treatment in September after a standard approval from the U.S. Food and Drug Administration in July.

(Reporting by Mariko Katsumura; Editing by Kirsten Donovan)

((Mariko.Katsumura@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.